In a First for Pharma, Citeline SmartSolutions Take AI to New Levels, Optimizing Clinical Trial Planning and Site Selection
13 Agosto 2024 - 8:00AM
Citeline, a leader in intelligence solutions for the life sciences
industry, has launched two new products — Protocol SmartDesign and
Investigator SmartSelect — in its Citeline SmartSolutions suite
accelerating the path from pipeline to patient. Citeline
SmartSolutions, an industry first, enables users to design and
conduct more predictable trials by connecting the robust data
assets already trusted by over 3,000 Citeline customers.
Incorporating artificial intelligence (AI) advanced machine
learning and large language models, Protocol SmartDesign harnesses
the power of Citeline’s Trialtrove and Sitetrove solutions.
Combining this industry-leading data with real-world and
proprietary performance data assets, Protocol SmartDesign helps the
life sciences industry build and deliver more predictable clinical
trials and accelerate clinical development. Researchers can:
- Rely on trial, site, investigator,
diversity and real-world data (RWD) to make decisions
- Receive recommendations on primary
endpoints and inclusion/exclusion (I/E) criteria
- Forecast enrollment rates by country
and trial duration by leveraging historical and performance
data
- Reduce the likelihood of costly
protocol amendments
- Streamline communication with a
centralized platform where teams can review, refine and finalize
the protocol, all in one place
Based on 20 years of experience as the leading source of
business intelligence for clinical trial investigator selection,
Investigator SmartSelect revolutionizes the process of country and
investigator selection.
Researchers can:
- Generate a pool of protocol-specific
investigators in minutes (compared to the traditional process that
can take four to six weeks)
- Identify, via a proprietary
algorithm, the optimal countries, site allocations and the best
investigators to deliver a clinical trial on time
- Leverage a unified user experience
and workflow in the integrated Citeline suite (Sitetrove and
Trialtrove) to further optimize feasibility and decision-making in
the planning stages
Both Protocol SmartDesign and Investigator SmartSelect help
study sponsors reduce costly protocol amendments and increase
predictability in clinical trial planning. According to a survey
conducted by the Tufts Center for the Study of Drug Development
(Tufts CSDD), protocol amendments cost an average of $141,000
each for Phase II trials and $535,000 each for Phase III trials. A
separate Tufts CSDD study revealed that protocols with at least one
amendment took much longer overall and at each clinical trial
segment.
“These solutions not only produce significant savings for
medical, clinical operations and feasibility teams in terms of both
time and cost, they ease the burden on study teams and site staff,”
said Maureen Ladouceur, RN, president of Norstella, Citeline’s
parent company. “As a clinician, this personally means a lot to
me.”
Citeline’s full array of complementary solutions and services
guides sponsors not only in the planning stages but throughout the
entire drug development lifecycle. For example, launched earlier
this year, Global Patient Insights provides an unsurpassed view of
the worldwide patient landscape, including diversity demographics,
and Citeline PatientMatch brings the process full circle by
pinpointing potential matches with identified
investigators.
“By helping sponsors reduce time to market,” said Norstella CEO
Mike Gallup, “we’re reinforcing Norstella’s mission of smoothing
the path to life-saving therapies for patients and providers — and,
ultimately, driving better outcomes."
To learn more about Citeline SmartSolutions, visit
Citeline.com.
About Citeline Citeline, a Norstella
company, powers a full suite of complementary business intelligence
offerings to meet the evolving needs of life science professionals
to accelerate the connection of treatments to patients and patients
to treatments. These patient-focused solutions and services deliver
and analyze data used to drive clinical, commercial and
regulatory-related decisions and create real-world opportunities
for growth.
Citeline’s global teams of analysts, journalists and consultants
keep their fingers on the pulse of the pharmaceutical, biomedical
and medtech industries, covering it all with expert insights: key
diseases, clinical trials, drug R&D and approvals, market
forecasts and more. For more information on one of the world’s most
trusted health science partners, visit Citeline and follow on
LinkedIn and X.
Citeline PR contact: Diffusion PR for
Citelinenorstella@diffusionpr.com (213) 318-4500